Letters Making medicines evergreen

Flynn Pharma’s reply to Brunet

BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f358 (Published 22 January 2013) Cite this as: BMJ 2013;346:f358
  1. David Walters, director1
  1. 1Flynn Pharma, Stevenage SG1 3EE, UK
  1. david.walters{at}flynnpharma.com

In response to Brunet,1 2 it is complex and expensive to manage the end of the life cycle of a declining product that is essential for patients. The most important consideration for patients was that the capsules were retained on the market, which would not have been …

View Full Text

Sign in

Log in through your institution